TAFA chemokine like family member 2Genealiases: FAM19A2 · TAFA-2
Q-omics provides the consensus-scored TAFA2 profile across patient tissues and cancer cell-line models. TAFA2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, TAFA2 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, TAFA2 RNA expression shows 19,817 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, COAD, and UVM as cancer lineages where TAFA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAFA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAFA2 survival associations across molecular data types. TAFA2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAFA2 RNA expression–survival associations across cancer types. High TAFA2 expression shows unfavorable associations in KICH and MESO, but favorable associations in UCS, PAAD, LGG and UCEC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for TAFA2 RNA expression.
This table summarizes TAFA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TAFA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAFA2 shows lower tumor expression in COAD, BLCA and KICH and higher tumor expression in THCA, CHOL and LIHC. The COAD box plot shows higher TAFA2 RNA expression in normal versus tumor tissue (log2 FC = −0.287, t-test p < 0.001).
This table shows molecular features associated with TAFA2 in patient tissues and cancer cell lines. In patient samples, TAFA2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TAFA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
